Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-03286-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Ege Arzuk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, Bornova, 35040, Izmir, Turkey. ege.arzuk@ege.edu.tr. Hauptthemen laut MEDLINE: Celecoxib, Inflammasomes, NLR Proteins, Interleukin-1beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ege University Research Foundation (BAP), Ege University.
Abstract (Originalsprache)
NLRP1 is predominantly overexpressed in breast cancer tissue, and the evaluated activation of NLRP1 inflammasome is associated with tumor growth, angiogenesis, and metastasis. Therefore, targeting NLRP1 activation could be a crucial strategy in anticancer therapy. In this study, we investigated the hypothesis that NLRP1 pathway may contribute to the cytotoxic effects of celecoxib and nimesulide in MDA-MB-231 cells. First of all, IC 50 values and inhibitory effects on the colony-forming ability of drugs were evaluated in cells. Then, the alterations in the expression levels of NLRP1 inflammasome components induced by drugs were investigated. Subsequently, the release of inflammatory cytokine IL-1β and the activity of caspase-1 in drug-treated cells were measured. According to our results, celecoxib and nimesulide selectively inhibited the viability of MDA-MB-231 cells. These drugs remarkably inhibited the colony-forming ability of cells. The expression levels of NLRP1 inflammasome components decreased in celecoxib-treated cells, accompanied by decreased caspase-1 activity and IL-1β release. In contrast, nimesulide treatment led to the upregulation of the related protein expressions with unchanged caspase-1 activity and increased IL-1β secretion. Our results indicated that the NLRP1 inflammasome pathway might contribute to the antiproliferative effects of celecoxib in MDA-MB-231 cells but is not a crucial mechanism for nimesulide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, Bornova, 35040, Izmir, Turkey. ege.arzuk@ege.edu.tr.
- Department of Biochemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.
Förderung
- Ege University Research Foundation (BAP)
- Ege University
Zitieren
APA
Arzuk, E., Birim, D., & Armağan, G. (2024). Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03286-2
Vancouver
Arzuk E, Birim D, Armağan G. Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-03286-2
BibTeX
@article{Arzuk2024,
author = {Arzuk, Ege and Birim, Derviş and Armağan, Güliz},
title = {Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-03286-2}
}
EUVIMED